Full Press Release Details
National Stock Exchange of India Ltd. (Scrip Code:
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
This is further to our intimation dated June 26,
2024, on the acquisition, by our wholly-owned subsidiary Dr. Reddy's Laboratories SA, Switzerland, of Haleon plc's global portfolio
of consumer healthcare brands in the Nicotine Replacement Therapy ("NRT") category outside of the United States, through the
purchase of shares of Northstar Switzerland SARL ("Northstar Switzerland"), a Haleon group company. We would like to inform
you that acquisition has now been completed, and the Company has made payment of upfront cash consideration of GBP 458 million. Further,
as part of this acquisition, Northstar Switzerland along with its wholly owned subsidiaries North Star OpCo Limited (United Kingdom) and
North Star Sweden AB (Sweden) are now wholly-owned step-down subsidiaries of the Company with effect from September 30, 2024.
Our acquired portfolio consists of Nicotinell,
a global leader in the NRT category with an extensive footprint in over 30 countries spanning Europe, Asia including Japan, and Latin
America, and local market-leading brand names of the product - Nicabate in Australia, Thrive in Canada, and Habitrol in New Zealand
and Canada. The portfolio is inclusive of all formats such as lozenge, patch, gum as well as pipeline products, in all applicable global
markets outside of the United States. Nicotinell is the second biggest brand globally (excluding the United States) in the NRT category.
NRT is recommended by the World Health Organization Model List of Essential Medicines' for nicotine use disorders. The acquisition
of this global portfolio of consumer healthcare products is a significant and logical extension of the Company's efforts in consumer
healthcare (nutrition and OTC wellness) in recent years, and of its purpose of Good Health Can't Wait'. The Company
has been steadily building its OTC presence in various markets and investing in its capabilities, including a recent joint venture with
Nestl India. As a business, consumer healthcare is a growing and sustainable business with favourable long-term trends. This acquisition
is an ideal anchor to continue to build the company's global consumer healthcare OTC business.
The details required under Regulation 30 of the
SEBI Listing Regulations, read with SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, have already been made available vide the
Annexure A' of our intimation dated June 26, 2024.
This is for your information and record.
For Dr. Reddy's Laboratories Limited
Company Secretary, Compliance Officer and Head-CSR